论文部分内容阅读
目的 探讨 mdm2与 p5 3基因在骨骼肌恶性肿瘤中的改变及其临床意义 .方法 采用 RNA打点杂交技术分析2 0例骨骼肌恶性肿瘤中的 mdm2与 p5 3基因的表达水平 ,采用 PCR- SSCP技术分析 p5 3基因的突变情况 ,结合随访结果 ,分析其临床意义 .结果 1RNA打点杂交结果 :mdm2基因在 10例恶性肿瘤标本中呈高表达 ,在 8例肿瘤标本与 2 0例瘤旁组织标本中呈低表达 ,mdm2的表达在骨骼肌恶性肿瘤中显著高于瘤旁组织 (P<0 .0 1) ;p5 3基因在 12例骨骼肌肿瘤标本中呈高表达 ,在相应瘤旁组织中呈低表达 ,两者之间存在显著性差异 (P<0 .0 1) ;2 PCR- SSCP未检出 mdm 2基因突变 ,检出 9例肿瘤标本中存在 p5 3基因突变 ;33a随访结果 :9例p5 3突变患者 ,3例死于术后 0 .5 a,4例死于术后 1a,2例死于术后 1.5 a,11例无 p5 3突变患者 ,6例死于术后 2 a,1例死于术后 3a,4例 3a后尚存活 .结论 mdm2基因以高表达方式 ,p5 3以突变、高表达方式参与骨骼肌恶性肿瘤发生发展 ,检测 mdm2有无高表达与 p5 3有无异常可辅助判断运动系统肿瘤患者的预后 .
Objective To investigate the changes of mdm2 and p53 genes in skeletal muscle malignancies and their clinical significance. Methods RNA interference hybridization was used to analyze the expression levels of mdm2 and p53 genes in 20 cases of skeletal muscle malignancies using PCR-SSCP technology. Analysis of p53 gene mutations, combined with follow-up results, analysis of its clinical significance. Results 1 RNA dot hybridization results: mdm2 gene was highly expressed in 10 cases of malignant tumors, in 8 cases of tumor specimens and 20 paraneoplastic tissue specimens Expression was low, mdm2 expression was significantly higher in skeletal muscle malignancies than in paratumor tissues (P < 0.01); p53 gene was highly expressed in 12 skeletal muscle tumor specimens and was present in corresponding paratumor tissues. Low expression, there was a significant difference between the two (P <0. 0 1); 2 mdm 2 gene mutation was not detected in PCR-SSCP, 9 cases of tumor samples were detected p53 gene mutation; 33a follow-up results: 9 Cases of p53 mutations, 3 died of 0.5 a postoperatively, 4 died of postoperative 1 a, 2 died of postoperative 1.5 a, 11 patients without p53 mutation, 6 died of postoperative 2 a , 1 case died of postoperative 3a, 4 cases survived after 3a. Conclusion mdm2 gene is highly expressed, p5 3 With mutations and high expressions involved in the development of skeletal muscle malignancies, detection of high expression of mdm2 and abnormal p53 may help determine the prognosis of patients with motor system tumors.